Cirrhosis Differential Diagnosis: A Comprehensive Guide for Accurate Liver Condition Assessment

Cirrhosis, the advanced stage of liver fibrosis, represents a significant global health challenge. Characterized by the replacement of normal liver tissue with scar tissue and regenerative nodules, this condition disrupts liver function and architecture. Chronic liver injury from various etiologies, including viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease, can lead to cirrhosis. Accurate diagnosis is paramount for effective management and improved patient outcomes. However, the clinical presentation of cirrhosis can overlap with a range of other hepatic and systemic disorders, necessitating a robust differential diagnosis approach. This article provides an in-depth exploration of the differential diagnosis of cirrhosis, aiming to equip healthcare professionals with the knowledge to distinguish cirrhosis from mimicking conditions and ensure precise patient care.

Etiology of Cirrhosis: Understanding the Root Causes

Cirrhosis is not a disease itself but rather the end-stage consequence of chronic liver damage. Understanding the diverse etiologies is crucial for both diagnosis and differential diagnosis. In developed countries, the primary culprits are:

Hepatitis C Virus (HCV): Chronic HCV infection remains a leading cause of cirrhosis, although effective antiviral treatments are changing this landscape.
Alcoholic Liver Disease (ALD): Excessive alcohol consumption is a major driver of liver damage and cirrhosis.
Nonalcoholic Steatohepatitis (NASH): Linked to obesity, diabetes, and metabolic syndrome, NASH is increasingly recognized as a dominant cause of cirrhosis.

Globally, Hepatitis B Virus (HBV) and HCV are still the most prevalent causes. Beyond these common etiologies, other significant causes include:

Autoimmune Hepatitis (AIH): An autoimmune disorder where the body’s immune system attacks liver cells.
Primary Biliary Cholangitis (PBC): A chronic cholestatic liver disease characterized by the destruction of small bile ducts.
Primary Sclerosing Cholangitis (PSC): A chronic cholestatic disease affecting both intrahepatic and extrahepatic bile ducts.
Hemochromatosis: A genetic disorder causing iron overload, leading to liver damage.
Wilson’s Disease: A genetic disorder resulting in copper accumulation in the liver and other organs.
Alpha-1 Antitrypsin Deficiency: A genetic condition that can cause liver and lung disease.
Budd-Chiari Syndrome: Hepatic venous outflow obstruction.
Drug-Induced Liver Injury (DILI): Certain medications and toxins can cause chronic liver damage and cirrhosis.
Cardiac Cirrhosis: Chronic right-sided heart failure leading to liver congestion and fibrosis.
Cryptogenic Cirrhosis: Cirrhosis of unknown origin, often presumed to be related to burned-out NASH or other unidentified factors.

Understanding these diverse etiologies is the first step in considering the broader differential diagnosis of cirrhosis, as some mimicking conditions may share similar underlying mechanisms or risk factors.

Epidemiology of Cirrhosis: Contextualizing the Prevalence

While the exact global prevalence is challenging to determine, cirrhosis is a significant health burden. Estimates in the United States suggest a prevalence between 0.15% and 0.27%. The epidemiology varies geographically and is influenced by the prevalence of the underlying etiologies. Regions with higher rates of viral hepatitis or alcohol consumption naturally exhibit a greater incidence of cirrhosis. Understanding the epidemiological context can be helpful in differential diagnosis, as the likelihood of certain conditions varies across populations.

Pathophysiology of Cirrhosis: Mechanisms of Liver Damage

Cirrhosis development is a complex process involving various liver cell types and molecular pathways. Chronic liver injury, regardless of the cause, triggers a cascade of events:

Hepatocyte Damage and Inflammation: Initial injury to hepatocytes leads to the release of inflammatory mediators and reactive oxygen species.
Hepatic Stellate Cell (HSC) Activation: HSCs, normally quiescent vitamin A-storing cells, are activated by inflammatory signals. They transform into myofibroblasts and become the primary collagen-producing cells in the liver.
Fibrogenesis: Activated HSCs deposit excessive extracellular matrix, including collagen, leading to fibrosis.
Sinusoidal Endothelial Cell (SEC) Dysfunction: Chronic injury disrupts the fenestrations in SECs, impairing exchange between sinusoids and hepatocytes and contributing to fibrosis.
Kupffer Cell Activation: Kupffer cells, liver-resident macrophages, release harmful mediators and contribute to inflammation and fibrosis.
Nodule Formation: As fibrosis progresses, regenerative nodules of hepatocytes attempt to replace damaged tissue, but this occurs in a disorganized manner within the fibrotic scar, disrupting the normal liver architecture.

The culmination of these processes is cirrhosis, characterized by widespread fibrosis and nodule formation, leading to impaired liver function and portal hypertension. Portal hypertension arises from increased intrahepatic resistance due to fibrosis and altered vascular regulation. This hemodynamic disturbance is a major driver of the clinical complications of cirrhosis.

Histopathology of Cirrhosis: Morphological Classification

Histopathological examination of liver tissue remains a crucial diagnostic tool for cirrhosis. Cirrhosis can be classified morphologically:

Micronodular Cirrhosis: Characterized by uniform nodules less than 3 mm in diameter. Often associated with alcohol abuse, hemochromatosis, and biliary obstruction.
Macronodular Cirrhosis: Features irregular nodules larger than 3 mm. More commonly linked to viral hepatitis (B and C), alpha-1 antitrypsin deficiency, and autoimmune hepatitis.
Mixed Cirrhosis: Displays features of both micronodular and macronodular patterns, often representing progression from micronodular to macronodular cirrhosis over time.

While morphological classification provides descriptive information, etiologic classification is more clinically relevant for guiding management. Etiologic classification categorizes cirrhosis based on the underlying cause, as listed in the Etiology section.

Understanding the histopathological features is important in differential diagnosis, as some mimicking conditions may also present with fibrosis or nodular changes, albeit with distinct patterns.

Figure 1: Liver Cirrhosis, Reticulin Stain 4×. Reticulin stain highlights the fibrous septa surrounding hepatic nodules in cirrhosis.

Figure 2: Cirrhosis, Liver. Reticulin stain enhances the fibrous septa dividing the hepatic nodules, ×4 magnification.

Clinical Presentation of Cirrhosis: Spectrum of Symptoms

Cirrhosis can present with a wide spectrum of clinical manifestations, ranging from asymptomatic compensated disease to overt decompensated cirrhosis with life-threatening complications.

Compensated Cirrhosis: In the early stages, patients may be asymptomatic. Cirrhosis might be incidentally detected through abnormal liver function tests (mildly elevated aminotransferases, GGT) or imaging studies performed for other reasons. Physical examination may reveal subtle hepatomegaly or splenomegaly.

Decompensated Cirrhosis: Transition to decompensation is marked by the development of major complications related to liver dysfunction and portal hypertension:

Ascites: Fluid accumulation in the peritoneal cavity, the most common complication of decompensation.
Jaundice: Yellowish discoloration of skin and sclera due to bilirubin accumulation.
Hepatic Encephalopathy (HE): Neuropsychiatric dysfunction ranging from subtle cognitive changes to coma, due to the liver’s inability to detoxify ammonia and other neurotoxins.
Variceal Hemorrhage: Bleeding from esophageal or gastric varices, dilated veins in the esophagus or stomach due to portal hypertension. A life-threatening emergency.
Hepatocellular Carcinoma (HCC): Primary liver cancer, a major long-term complication of cirrhosis.

Other complications include spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and hepatopulmonary syndrome (HPS).

Systemic Manifestations: Cirrhosis can affect multiple organ systems:

Gastrointestinal: Portal hypertensive gastropathy, small intestinal bacterial overgrowth (SIBO), increased gallstone risk.
Hematologic: Anemia, thrombocytopenia, coagulopathy (impaired clotting).
Renal: Hepatorenal syndrome (HRS), electrolyte imbalances (hyponatremia).
Pulmonary: Hepatopulmonary syndrome (HPS), portopulmonary hypertension, hepatic hydrothorax.
Dermatologic: Spider nevi, palmar erythema, jaundice.
Endocrine: Hypogonadism, gynecomastia.
Nail Changes: Clubbing, Terry’s nails.
Other: Fetor hepaticus (sweet, musty breath odor), asterixis (liver flap).

The diverse clinical presentation underscores the importance of considering a broad differential when cirrhosis is suspected. Many of these signs and symptoms can be non-specific and overlap with other conditions.

Evaluation of Cirrhosis: Diagnostic Modalities

Diagnosis of cirrhosis involves a combination of clinical assessment, laboratory investigations, imaging, and liver biopsy in certain cases.

Laboratory Findings:

Liver Function Tests (LFTs):
- Aminotransferases (AST, ALT): Usually mildly to moderately elevated, AST often higher than ALT (AST/ALT ratio >1, especially in alcoholic cirrhosis). Normal levels do not rule out cirrhosis.
- Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT): May be elevated, particularly in cholestatic cirrhosis.
- Bilirubin: Elevated in decompensated cirrhosis and cholestatic conditions.
- Albumin: Reduced in advanced cirrhosis due to impaired synthetic function.
- Prothrombin Time (PT)/INR: Prolonged due to decreased production of clotting factors.
Complete Blood Count (CBC): Anemia (normochromic or macrocytic), thrombocytopenia, leukopenia may be present.
Serology: To identify the etiology: Viral hepatitis markers (HBV, HCV, HDV), autoimmune antibodies (ANA, ASMA, anti-LKM1), anti-mitochondrial antibody (AMA).
Specific Tests: Ferritin and transferrin saturation (hemochromatosis), ceruloplasmin and urinary copper (Wilson’s disease), alpha-1 antitrypsin level, serum alpha-fetoprotein (AFP) for HCC screening.

Imaging Studies:

Ultrasound: Detects liver nodularity, increased echogenicity, splenomegaly, ascites. Doppler ultrasound assesses hepatic and portal vein patency and flow direction.
CT and MRI: Provide detailed liver morphology, detect HCC, vascular lesions, and assess for fat or iron deposition. MRI is superior for HCC detection.
Transient Elastography (FibroScan): Non-invasive assessment of liver stiffness, correlates with fibrosis stage.
Esophagogastroduodenoscopy (EGD): To screen for esophageal and gastric varices in patients with portal hypertension.

Liver Biopsy:

Gold Standard: Remains the definitive diagnostic test for confirming cirrhosis and assessing etiology, grade (inflammation), and stage (fibrosis).
Limitations: Sampling error can occur. Not always necessary if clinical, laboratory, and imaging findings are conclusive.

Cirrhosis Differential Diagnosis: Mimicking Conditions

The differential diagnosis of cirrhosis is broad and includes various acute and chronic liver diseases, as well as systemic conditions that can present with similar clinical or laboratory features. It is crucial to systematically consider and exclude these alternative diagnoses.

1. Acute Liver Failure (ALF):

Conditions: Acute viral hepatitis (A, B, E), drug-induced liver injury (acetaminophen overdose, idiosyncratic DILI), ischemic hepatitis, autoimmune hepatitis, Wilson’s disease, acute fatty liver of pregnancy (AFLP), HELLP syndrome, Amanita mushroom poisoning.
Differentiation: ALF is characterized by rapid onset of jaundice, coagulopathy, and encephalopathy in a previously healthy liver. In contrast, cirrhosis develops over years of chronic liver injury. History of acute illness, specific drug exposure, or pregnancy context are important clues. Liver biopsy in ALF typically shows massive necrosis or fulminant inflammation, distinct from the fibrosis and nodule formation in cirrhosis.

2. Chronic Hepatitis without Cirrhosis:

Conditions: Chronic viral hepatitis (B, C), non-alcoholic fatty liver disease (NAFLD) with steatosis or steatohepatitis (NASH) but without advanced fibrosis, autoimmune hepatitis (early stages), primary biliary cholangitis (early stages), primary sclerosing cholangitis (early stages).
Differentiation: These conditions represent earlier stages of liver disease that can progress to cirrhosis. Absence of clinical signs of portal hypertension (ascites, varices, splenomegaly) and preserved liver synthetic function suggest chronic hepatitis without cirrhosis. Liver biopsy is crucial to differentiate fibrosis stage. Transient elastography can also help assess fibrosis non-invasively.

3. Biliary Obstruction (Cholestasis):

Conditions: Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), bile duct strictures, choledocholithiasis, biliary tumors.
Differentiation: Cholestatic conditions can cause jaundice, elevated ALP and GGT, and pruritus, similar to cholestatic cirrhosis. However, prominent pruritus, elevated ALP disproportionate to aminotransferases, and specific imaging findings (bile duct dilation on ultrasound or MRCP) are suggestive of biliary obstruction. Autoimmune markers (AMA for PBC, pANCA for PSC) are helpful. Liver biopsy in PBC and PSC shows characteristic biliary lesions, distinct from cirrhosis.

4. Benign Liver Tumors and Nodular Hyperplasia:

Conditions: Focal nodular hyperplasia (FNH), hepatocellular adenoma, hemangioma, nodular regenerative hyperplasia (NRH).
Differentiation: These conditions can present with liver nodules on imaging, mimicking macronodular cirrhosis. Absence of clinical and laboratory evidence of chronic liver disease or portal hypertension is key. Specific imaging characteristics (contrast enhancement patterns on CT/MRI) and liver biopsy can differentiate benign lesions from cirrhosis. NRH, while non-neoplastic, can cause portal hypertension and be difficult to distinguish from cirrhosis clinically and radiologically, requiring biopsy.

5. Vascular Liver Diseases:

Conditions: Budd-Chiari syndrome (hepatic vein obstruction), portal vein thrombosis, sinusoidal obstruction syndrome (veno-occlusive disease), cardiac cirrhosis (congestive hepatopathy).
Differentiation: These conditions primarily affect liver vasculature. Clinical history (hypercoagulable state, myeloproliferative disorders for Budd-Chiari; heart failure for cardiac cirrhosis), specific imaging findings (vascular obstruction on Doppler ultrasound, CT/MRI), and absence of typical cirrhosis etiologies are important. Cardiac cirrhosis shows centrilobular fibrosis, different from the diffuse fibrosis of other cirrhosis types.

6. Metabolic Liver Diseases:

Conditions: Hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, glycogen storage diseases, galactosemia, fructose intolerance.
Differentiation: These genetic metabolic disorders can cause chronic liver disease and cirrhosis if untreated. Family history, younger age of onset, extrahepatic manifestations (neurological, ophthalmological in Wilson’s; lung disease in alpha-1 antitrypsin deficiency), and specific laboratory tests (iron studies, ceruloplasmin, alpha-1 antitrypsin levels) are crucial for diagnosis.

7. Systemic Conditions with Liver Involvement:

Conditions: Congestive heart failure, amyloidosis, sarcoidosis, lymphoma, metastatic liver disease.
Differentiation: These systemic diseases can secondarily affect the liver and cause hepatomegaly, abnormal LFTs, or even portal hypertension in some cases. Clinical context of underlying systemic disease, extrahepatic manifestations, and specific diagnostic tests for the systemic condition are crucial. Liver biopsy may show features of the systemic disease (e.g., amyloid deposition, granulomas in sarcoidosis, tumor infiltration in metastasis).

8. Pregnancy-Related Liver Conditions (Beyond AFLP and HELLP in ALF section):

Conditions: Intrahepatic cholestasis of pregnancy (ICP).
Differentiation: ICP presents with pruritus and jaundice in pregnancy, but typically without coagulopathy or encephalopathy seen in ALF or decompensated cirrhosis. LFT abnormalities are usually milder. ICP resolves after delivery.

9. Drug-Induced Liver Injury (DILI) – Chronic DILI:

Conditions: Chronic DILI from certain medications (methotrexate, amiodarone, isoniazid, nitrofurantoin, herbal supplements).
Differentiation: History of long-term medication use known to cause chronic liver injury is key. DILI can mimic any form of chronic liver disease, including cirrhosis. Causality assessment (RUCAM scale) and exclusion of other etiologies are important. Liver biopsy may show specific patterns depending on the drug.

Prognosis and Complications: Understanding Disease Progression

The prognosis of cirrhosis varies greatly depending on the stage of disease and underlying etiology. Compensated cirrhosis has a better prognosis than decompensated cirrhosis. Predictive models like Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD) scores are used to assess disease severity and predict prognosis. Liver transplantation is the definitive treatment for decompensated cirrhosis.

Complications of cirrhosis include portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, and hepatocellular carcinoma. Early diagnosis and management are essential to prevent or delay these complications and improve patient survival.

Deterrence and Patient Education: Lifestyle Modifications

While cirrhosis itself is often irreversible, further liver damage can be prevented by addressing the underlying cause and adopting healthy lifestyle modifications:

Abstinence from Alcohol: Crucial for ALD-related cirrhosis.
Weight Loss and Dietary Changes: For NASH-related cirrhosis, aiming for a balanced diet and weight reduction.
Antiviral Therapy: For viral hepatitis-related cirrhosis, effective antiviral treatments can halt progression and even lead to regression of fibrosis in some cases.
Vaccination: Vaccination against HBV and HAV (if not already immune) is recommended.
Low-Sodium Diet: For ascites management.
Avoidance of Hepatotoxic Medications: Caution with NSAIDs and other drugs metabolized by the liver.
Regular Monitoring: Surveillance for HCC and varices is essential.

Patient education is vital to empower individuals to actively participate in their care and make informed decisions about lifestyle modifications and treatment adherence.

Conclusion: The Importance of Accurate Differential Diagnosis

Cirrhosis represents a significant clinical entity with a wide range of etiologies, clinical presentations, and potential mimicking conditions. A comprehensive approach to differential diagnosis is paramount to ensure accurate diagnosis and appropriate management. This involves a thorough assessment of clinical history, physical examination, laboratory investigations, imaging studies, and liver biopsy when indicated. By systematically considering and excluding alternative diagnoses, healthcare professionals can optimize patient care, improve outcomes, and ultimately enhance the quality of life for individuals affected by liver disease.

Figure 3: Schistosomiasis Infection. Photomicrograph of liver tissue showing pipe stem cirrhosis in schistosomiasis. While schistosomiasis is a cause of cirrhosis, it is less common in Western countries and should be considered in the context of patient travel history.

Figure 4: Cirrhosis, Portal Space in Fibrous Septa. Reticulin stain 4×. Histopathology is essential for confirming cirrhosis and often for differentiating it from other liver conditions.

Figure 5: Liver Cirrhosis, Trichrome Stain, 4×. Trichrome stain highlights collagen (blue) in the fibrotic septa of cirrhosis.

References

Naveau S, Perlemuter G, Balian A. [Epidemiology and natural history of cirrhosis]. Rev Prat. 2005 Sep 30;55(14):1527-32. [PubMed: 16255293]
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 08;371(9615):838-51. [PMC free article: PMC2271178] [PubMed: 18328931]
Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol. 2015 Sep;49(8):690-6. [PubMed: 25291348]
Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002 Aug 23;1(1):1. [PMC free article: PMC131011] [PubMed: 12437787]
Deaciuc IV, D’Souza NB, Fortunato F, Hill DB, Sarphie TG, McClain CJ. Alcohol-induced sinusoidal endothelial cell dysfunction in the mouse is associated with exacerbated liver apoptosis and can be reversed by caspase inhibition. Hepatol Res. 2001 Jan 01;19(1):85-97. [PubMed: 11137483]
Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006 Dec 14;12(46):7413-20. [PMC free article: PMC4087584] [PubMed: 17167827]
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005 Feb;115(2):209-18. [PMC free article: PMC546435] [PubMed: 15690074]
Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2010 Dec;16(4):347-52. [PMC free article: PMC3304610] [PubMed: 21415576]
Kim MY, Baik SK. [Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension]. Korean J Gastroenterol. 2009 Sep;54(3):143-8. [PubMed: 19844149]
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W., Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922-38. [PubMed: 17879356]
Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, López Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1996 Mar;41(3):552-6. [PubMed: 8617135]
Sheen IS, Liaw YF. The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. Hepatology. 1989 Apr;9(4):538-40. [PubMed: 2925157]
John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol. 2015 Mar 21;21(11):3197-205. [PMC free article: PMC4363748] [PubMed: 25805925]
Lata J. Hepatorenal syndrome. World J Gastroenterol. 2012 Sep 28;18(36):4978-84. [PMC free article: PMC3460323] [PubMed: 23049205]
Pirovino M, Linder R, Boss C, Köchli HP, Mahler F. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr. 1988 Apr 01;66(7):298-302. [PubMed: 3131572]
Green GR. Mechanism of hypogonadism in cirrhotic males. Gut. 1977 Oct;18(10):843-53. [PMC free article: PMC1411687] [PubMed: 590844]
Van den Velde S, Nevens F, Van Hee P, van Steenberghe D, Quirynen M. GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):344-8. [PubMed: 18938115]
Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol. 1978 Aug;70(2):248-58. [PubMed: 696683]
Ballard HS. The hematological complications of alcoholism. Alcohol Health Res World. 1997;21(1):42-52. [PMC free article: PMC6826798] [PubMed: 15706762]
Tanaka S, Okamoto Y, Yamazaki M, Mitani N, Nakqjima Y, Fukui H. Significance of hyperglobulinemia in severe chronic liver diseases–with special reference to the correlation between serum globulin/IgG level and ICG clearance. Hepatogastroenterology. 2007 Dec;54(80):2301-5. [PubMed: 18265652]
Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med. 2002 Sep;21(9):1023-32; quiz 1033-4. [PubMed: 12216750]
Giorgio A, Amoroso P, Lettieri G, Fico P, de Stefano G, Finelli L, Scala V, Tarantino L, Pierri P, Pesce G. Cirrhosis: value of caudate to right lobe ratio in diagnosis with US. Radiology. 1986 Nov;161(2):443-5. [PubMed: 3532188]
Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, Brú C, Bruix J., Barcelona Clínic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003 Oct;38(4):1034-42. [PubMed: 14512891]
Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614-8. [PubMed: 12385448]
Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):22-39. [PubMed: 18973844]
Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003 Aug;39(2):222-30. [PubMed: 12873819]
Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B. BMC Gastroenterol. 2014 Jul 03;14:118. [PMC free article: PMC4086988] [PubMed: 24990385]
Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010 Jan;51(1):121-9. [PMC free article: PMC2799538] [PubMed: 19827166]
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R., United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan;124(1):91-6. [PubMed: 12512033]
Vinaixa C, Rubín A, Aguilera V, Berenguer M. Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol. 2013;26(4):304-313. [PMC free article: PMC3959489] [PubMed: 24714603]
Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun. 2020 Nov;4(11):1562-1577. [PMC free article: PMC7603526] [PubMed: 33163829]
Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013 Jul;47 Suppl(0):S2-6. [PMC free article: PMC3683119] [PubMed: 23632345]